The strategic claim behind Gulf biotechnology is that the region is becoming a producer, investor, research base and exporter rather than a market that foreign companies enter. The first three are demonstrably underway. The fourth is the next stage, and A7i's exports dataset is deliberately selective, because its value lies in measuring that stage precisely.
What qualifies
An export is Gulf-owned or Gulf-developed capability reaching a market outside the GCC. Imported technology, inbound licensing and local distribution of foreign products are tracked elsewhere on this site, however large. This dataset measures the outward direction.
What A7i has verified
Two outbound acquisitions, both by PureHealth and both into the United Kingdom. The Circle Health Group acquisition completed in January 2024, with consideration reported at $1.2bn, gave an Abu Dhabi group operational control of the largest private hospital operator in Britain. In September 2026 PureHealth took over selected Unilabs laboratory operations, including hub laboratories at Euston and Cavendish Square, covering pathology, histopathology, blood sciences, microbiology and specialist diagnostics across a network serving more than fifty hospitals and more than ninety external clients.
One Gulf-developed product with foreign customers: WAYAKIT, a KAUST spinout manufacturing in Jeddah, which holds ground-handling agreements in foreign countries alongside its nationwide Saudi Ground Services contract.
One state manufacturer with facilities abroad: Mubadala Bio, which operates across Asia, Africa and Europe. And Arcera, reported to commercialise medicines across more than 90 markets with manufacturing in eight countries, a figure A7i holds outside the count until an Arcera or ADQ document confirms it.
The next milestones
Four firsts will mark the next stage. The first out-licence of a Gulf-originated therapeutic, diagnostic or platform to a company outside the region. The first marketing authorisation for a Gulf-developed medicine or device from a regulator outside the GCC. The first Gulf-originated biotechnology patent family with international grants. And the first Gulf asset in a foreign clinical trial, reversing today's pattern in which partnerships bring foreign assets into Gulf trials.
The distinction that matters
The two acquisitions are substantial, and they are distinct from exporting. Capital buying foreign capability moves value into the region. Gulf capability being sold abroad moves value out of the region and back as revenue. The first is what sovereign wealth has always done. The second is what a producer economy does, and it is the stage now ahead.
Every manufacturing economy that eventually exported technology went through a period of licensing it in first, and the Gulf is roughly three years into a programme designed to take twenty. The useful thing is to measure the right variable. Announced capital, new facilities and regulatory milestones all describe the inward build. The outward record is the one that will show the build working, and it already includes two acquisitions in Britain and a KAUST spinout with foreign customers.